Bone Loss
Bone Loss
Zoledronate Protects HIV Positive Men against Bone Loss for at Least 5 Years
- Details
- Category: Bone Loss
- Published on Tuesday, 10 April 2012 00:00
- Written by Gregory Fowler
The effects of 2 annual doses of zoledronate persist for at least 5 years in HIV positive men on antiretroviral therapy (ART), according to a New Zealand study published in the March 14, 2012, advance online edition of the Journal of Clinical Endocrinology & Metabolism.
CROI 2012: Switching to Tenofovir Increases Bone Turnover, Raltegravir Can Improve Bone Density
- Details
- Category: Bone Loss
- Published on Tuesday, 10 April 2012 00:00
- Written by Liz Highleyman
HIV positive people who substituted tenofovir (Viread) for zidovudine (AZT; Retrovir) in their antiretroviral regimen showed elevated levels of biomarkers associated with bone turnover and decreased bone mineral density (BMD), researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last month in Seattle. A related study found that switching from tenofovir to raltegravir (Isentress) led to increases in bone density.
Vitamin D May Improve Bone Health in Young HIV+ People Taking Tenofovir
- Details
- Category: Bone Loss
- Published on Tuesday, 17 January 2012 00:00
- Written by NIH
Taking vitamin D supplements may help prevent hormonal changes linked to bone loss among young adults whose antiretroviral regimen includes tenofovir (Viread, also in the Truvada and Atripla combination pills), according to a recent announcement from the National Institutes of Health (NIH).
Conflicting Data on Bone Fracture Link to HIV Meds
- Details
- Category: Bone Loss
- Published on Tuesday, 07 February 2012 00:00
- Written by Liz Highleyman
Overall, use of antiretroviral therapy (ART) appears to be associated with a decreased likelihood of bone fractures among people with HIV, but whether specific drugs such as tenofovir increase the risk, reduce the risk, or have a variable effect over time remains unclear based on conflicting data reported in the February 1, 2012, advance online edition of AIDS.
HIV+ People on ART Have Stable Bone Density after Short-term Loss
- Details
- Category: Bone Loss
- Published on Tuesday, 13 September 2011 00:00
- Written by Liz Highleyman
People with HIV tend to experience a loss of bone mineral density soon after starting antiretroviral therapy (ART), but the decline reaches a plateau after about 1 year and remains quite stable thereafter, according to a meta-analysis of nearly 40 studies described in the September 2011 Journal of Clinical Endocrinology and Metabolism.
Web Design and Development by